PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 834124

FDA considerations regarding new hypolipidemic agents.

M J Finkel
View original source ↗Export metadata ↓

Abstract

Food and Drug Administration policy being considered for new marketed hypolipidemic agents includes: long-term safety to be demonstrated in postmarketing studies; evidence of clinical effectiveness to be demonstrated within a specified time period. Effectiveness is to be judged by one or more of the following: reduction in xanthomata, reduction atherosclerotic plaque, reduction in morbidity of coronary artery disease or peripheral and cerebral atherosclerosis, and reduction in mortality. Randomized double blind trials are deemed necessary.

Explore related subjects

Hypolipidemic AgentsNational Institutes of Health (U.S.)United StatesUnited States Food and Drug AdministrationJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M J Finkel. 1977. FDA considerations regarding new hypolipidemic agents.. https://doi.org/10.1007/bf02532974

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2005

FR177391, a new anti-hyperlipidemic agent from Serratia. III. Microbial conversion of FR177391 and synthesis of FR177391 derivatives for its target protein screening by chemical genetic approaches.

FR177391 produced by Serratia liquefaciens No. 1821 enhances differentiation of mouse 3T3-L1 fibroblasts to adipocytes and reduces the circulating levels of triglyceride in C57BL/KsJ-db/bd mice, an obese non-insulin-dependent diabetes mellitus animal model, although its mechanism of actions remained to be unknown. Its active derivative, 20-hydroxy FR177391, and its inactive derivative, 3-hydroxy FR177391 were produced by microbial conversion of FR177391, and biotin-labeled FR177391 was synthesized from 20-hydroxy FR177391 as an active affinity ligand to identify target molecules of FR177391 by chemical genetic approaches.

Hypolipidemic Agents↗
PubMed1992

Influence of inhibitors of lipid biosynthesis on the production of avermectins in Streptomyces avermitilis.

Streptomyces avermitilis was grown in the presence of four inhibitors of fatty acid biosynthesis (p-chlorophenoxyacetic, DL-2-(p-chlorophenoxy)-propionic, 2-(p-chlorophenoxy)-2-methyl-propionic and p-fluorophenoxyacetic acids). The production of total lipids was inhibited and the cellular content of individual types of fatty acids was altered by these compounds. The anteiso-acid content decreased by up to one-half, whereas the content of iso-odd acids increased 10-fold in the presence of inhibitors. The decrease in anteiso-acids was accompanied by increased production of avermectins having a s-butyl group in the side chain (type 'a' avermectins). It was concluded that the common precursor, 2-methylbutyryl-CoA, was diverted from the biosynthetic pathway of fatty acids to that of avermectins.

Hypolipidemic Agents↗